RxDoctor Payments Data

Ehab Mady, DO

Phlebology · Newport Beach, CANPI 1265600795

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $128,225 of the $174,091 with a category attached, or 73.7%. Johnson & Johnson accounts for 83.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $64,944 and has fallen 92.6% since, to $4,800 in 2025.

$174,091in general payments, 2019–2025

Across 149 payments — averaging $1168.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$146K
  • Angiodynamics, Inc.$28K
  • E.r. Squibb & Sons, L.L.C.$189

What the payments were for

  • Consulting fees$3,2002%
  • Speaking & faculty fees$128,22574%
  • Travel & lodging$11,6527%
  • Food & beverage$3,1342%
  • Education$8,6805%
  • Other$19,20011%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson125$146,022
Angiodynamics, Inc.8$27,880
E.r. Squibb & Sons, L.L.C.16$189

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few phlebology providers in Californiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$450,476
Medicare patients
668
Services billed
2,891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban525$568,071
XareltoRivaroxaban419$455,434
Rosuvastatin Calcium45$963
Doxycycline Hyclate80$596
Atorvastatin Calcium47$555
Potassium Chloride18$432
Triamcinolone Acetonide34$208
ClopidogrelClopidogrel Bisulfate15$190
Furosemide29$175
Nifedipine ErNifedipine22$118
Hydrochlorothiazide17$117
Amlodipine Besylate29$82
Lisinopril17$17

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$146,022$455,434419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few phlebology providers in Californiaon file to place this against a meaningful peer group, so we don't.

Other phlebology in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →